Managing head and neck atopic dermatitis (AD) presents a significant challenge for dermatologists due to the visibility and sensitivity of these areas. Recent findings have highlighted the potential of Upadacitinib for atopic dermatitis as a potent therapeutic option. This post hoc analysis utilized data from the Measure Up 1 and Measure Up 2 trials to determine how effective this JAK inhibitor is for localized head and neck involvement.

The study evaluated adult and adolescent patients who received either 15 mg or 30 mg of upadacitinib once daily. Researchers specifically looked at stringent targets such as the Eczema Area and Severity Index (EASI) 90 and EASI 100. Consequently, the analysis provides clear insights into the drug's performance within this patient population.

Clinical Efficacy of Upadacitinib for Atopic Dermatitis

At week 16, the data showed impressive results for both dosages. Specifically, 46.8% of patients on the 15 mg dose and 58.0% on the 30 mg dose achieved nearly clear skin. In contrast, only 13.5% of the placebo group reached similar outcomes. Furthermore, the median reduction in EASI scores was 87.8% and 96.3% for the two respective doses. These results indicate that upadacitinib works rapidly and effectively.

In addition to skin clearance, the study tracked patient-reported outcomes. Patients reported significant improvements in symptoms and quality of life. Moreover, these benefits remained consistent across different baseline severity levels. Therefore, clinicians can consider upadacitinib a robust option for patients suffering from moderate to severe facial and neck eczema.

Improved Patient Outcomes and Quality of Life

The analysis demonstrates that upadacitinib offers a substantial advantage in managing visible disease. Because head and neck AD impacts social interactions, achieving near-complete clearance is a primary goal. Notably, the high rates of EASI 90 and EASI 100 suggest that many patients can achieve skin that is almost entirely clear of lesions.

Frequently Asked Questions

What were the primary skin clearance targets in the study?

The study focused on achieving head and neck EASI ≤ 0.3, EASI 90 (90% clearance), and EASI 100 (100% clearance) by week 16 of treatment.

How did the 30 mg dose compare to the 15 mg dose?

While both doses showed high efficacy, the 30 mg dose generally achieved higher rates of complete skin clearance (42.4%) compared to the 15 mg dose (29.1%).

Are the results consistent across different severity levels?

Yes, the efficacy of upadacitinib remained consistent regardless of the patient's baseline head and neck eczema severity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author or publisher. While we strive for accuracy, medical knowledge is constantly evolving. Refer to the latest local and national guidelines for clinical practice.

References

Eyerich K et al. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region. Dermatol Ther (Heidelb). 2026 May 24. doi: 10.1007/s13555-026-01793-z. PMID: 42177735.

Guttman-Yassky E, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168.

Simpson EL, et al. Efficacy and safety of upadacitinib in patients with atopic dermatitis: A phase 2a, randomized, placebo-controlled study. J Am Acad Dermatol. 2017 Sep;77(3):388-397.e1.